Palatin Technologies has filed a patent for formulations and methods to treat sexual dysfunction in females with controlled hypertension. The patent claims a method involving multiple subcutaneous injections of a composition containing bremelanotide or its salt, with specific dosage and frequency guidelines. The invention aims to effectively treat female sexual dysfunction in patients with controlled hypertension. GlobalData’s report on Palatin Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Palatin Technologies, cyclosporin derivatives was a key innovation area identified from patents. Palatin Technologies's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of sexual dysfunction in females with controlled hypertension
A recently filed patent (Publication Number: US20230158118A1) describes a method for treating female sexual dysfunction in patients diagnosed with the condition. The method involves administering more than a single subcutaneous injection of a composition containing bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the patient when they are anticipating sexual activity. The composition should have a net peptide weight of 1.00 mg to 1.75 mg of bremelanotide. There should be at least 24 hours between each injection, and no more than eight injections should be given in a month. This treatment approach aims to effectively treat female sexual dysfunction.
The patent also outlines that the composition should result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration. The patients who can benefit from this method are those with controlled hypertension. The method specifies that the patient should not be taking more than two anti-hypertensive drugs and should consistently maintain their systolic blood pressure below 130 mm Hg and diastolic blood pressure below 80 mm Hg.
The composition described in the patent is an aqueous solution containing an acetate salt of bremelanotide. It may also include glycerin, with a concentration of 2.5% glycerin (w/v). The composition has a pH of 5.0 and may contain agents such as hydrochloric acid and sodium hydroxide to adjust the pH. The variability in peak plasma concentration within 60 minutes after subcutaneous administration of the composition should be less than 30% coefficient of variation (% CV).
The patent further specifies that the female sexual dysfunction being treated can include decreased sexual desire, hypoactive sexual desire disorder, hypoactive sexual desire disorder with female sexual arousal disorder, or hypoactive sexual desire disorder without female sexual arousal disorder. The composition is provided in a single-use pre-filled syringe for convenience and ease of administration.
Overall, this patent presents a method for treating female sexual dysfunction using subcutaneous injections of a specific composition containing bremelanotide or its salt. The method takes into account factors such as controlled hypertension, dosage, timing, and the desired peak plasma concentration of bremelanotide. This treatment approach aims to address various forms of female sexual dysfunction and provides specific guidelines for administration.
To know more about GlobalData’s detailed insights on Palatin Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
